拓扑替康与拓扑替康联合美法仑治疗视网膜母细胞瘤玻璃体腔种植的疗效比较
回顾性队列研究纳入2015年12月至2025年5月复旦大学附属眼耳鼻喉科医院34例单眼玻璃体腔种植的视网膜母细胞瘤患儿,比较玻璃体腔注射拓扑替康单药与联合美法仑的疗效与安全性。两组玻璃体腔种植均100%控制、无眼眶或全身转移;单药组白内障和眼球萎缩发生率更低(均P<0.05),最终保眼率14/15与14/19差异无统计学意义(P>0.05)。
要点
- 两组玻璃体腔种植均100%控制,无眼眶或全身转移。
- 单药组白内障0/15 vs 双药组9/19、眼球萎缩0/15 vs 6/19(均P<0.05)。
- 最终保眼率单药组14/15 vs 双药组14/19,差异无统计学意义(P>0.05)。
核心结论
- 玻璃体腔注射拓扑替康能有效治疗视网膜母细胞瘤玻璃体腔种植。
- 与联合美法仑方案相比,单独采用拓扑替康的眼内不良反应更小。
研究设计与样本
- 回顾性队列研究,收集2015年12月至2025年5月在复旦大学附属眼耳鼻喉科医院诊治的34例单眼玻璃体腔种植的视网膜母细胞瘤患儿临床资料。
- 患儿均在接受经静脉化学治疗或经动脉介入化学治疗后出现顽固性或复发性玻璃体腔种植,接受玻璃体腔注射拓扑替康(单药组15只眼)或联合玻璃体腔注射美法仑(双药组19只眼),每4周1次,直至玻璃体腔种植消失或钙化稳定。
主要发现
- 共34例患儿(34只眼),男性21例(61.8%)、女性13例(38.2%),初次诊断年龄29.5(19.5,38.0)个月;双眼视网膜母细胞瘤8例(23.5%),单眼26例(76.5%)。
- 患眼左眼15只(44.1%)、右眼19只(55.9%);国际眼内视网膜母细胞瘤分期E期13只(38.2%)、D期20只(58.8%)、C期1只(3.0%)。
- 单药组15只眼(44.1%),初次诊断年龄21.0(11.0,30.0)个月,随访时间19.0±10.0个月,C期1只、D期7只、E期7只,每只眼注射3.1±1.1次,拓扑替康总剂量89.3±34.3 μg。
- 双药组19只眼(55.9%),初次诊断年龄33.0(22.0,42.0)个月,随访时间67.9±30.4个月,D期13只、E期6只,每只眼注射5.0±1.7次,美法仑总剂量111.1±44.5 μg、拓扑替康总剂量74.7±44.0 μg。
- 随访期两组所有患眼玻璃体腔种植均得到控制(100%),无眼眶或全身转移;单药组白内障0/15 vs 双药组9/19、眼球萎缩0/15 vs 6/19(均P<0.05);视网膜脉络膜萎缩、血管闭塞、视神经萎缩差异均无统计学意义(均P>0.05);最终保眼率单药组14/15 vs 双药组14/19,差异无统计学意义(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To comparatively evaluate the efficacy and safety of intravitreal topotecan (IVT) versus intravitreal melphalan (IVM) combined with IVT in the treatment of vitreous seeds in retinoblastoma (RB). Methods: Retrospective cohort study. This study collected clinical data from 34 patients with unilateral vitreous seeds in RB who were diagnosed and treated at the Department of Ophthalmology of Eye & ENT Hospital of Fudan University from December 2015 to May 2025. All patients developed refractory or recurrent vitreous seeds after receiving intravenous chemotherapy or intra-arterial chemotherapy. Baseline data, ocular characteristics and detailed treatment histories were analyzed. Patients were treated with IVT (single-drug group) or IVT combined with IVM (double-drug group), which was administered at 4-week intervals until the vitreous seeds disappeared or became stably calcified. The primary outcome measures were the control of vitreous seeds and the globe-salvage rate. The ocular and systemic adverse effects following intravitreal chemotherapy were also recorded. Statistical analyses were performed using the t test, the Mann-Whitney U test and the χ² test. The Kaplan-Meier method was used to plot globe-salvage curves and differences were compared using the log-rank test. Results: There were 21 (61.8%) males and 13 (38.2%) females. The median age at initial diagnosis was 29.5 (19.5, 38.0) months. Among them, 8 (23.5%) had bilateral RB, all with unilateral vitreous seeds and the affected eye received intravitreal chemotherapy and 26 (76.5%) had unilateral RB. Of the affected eyes, 15 (44.1%) were left eyes and 19 (55.9%) were right eyes. According to the International Intraocular Classification of Retinoblastoma, 13 (38.2%) eyes were classified as group E, 20 (58.8%) as group D, and 1 (3.0%) as group C. The single-drug group included 15 eyes (44.1%), with a median age at initial diagnosis of 21.0 (11.0, 30.0) months and a follow-up duration of 19.0±10.0 months. Among them, 1 eye was classified as group C, 7 eyes as group D, and 7 eyes as group E. Each affected eye received a mean of 3.1±1.1 intravitreal injections, with a total topotecan dose of 89.3±34.3 μg per eye. The double-drug group included 19 eyes (55.9%), with a median age at initial diagnosis of 33.0 (22.0, 42.0) months and a follow-up duration of 67.9±30.4 months. Among them, 13 eyes were classified as group D and 6 eyes as group E. Each affected eye received a mean of 5.0±1.7 intravitreal injections, with a total melphalan dose of 111.1±44.5 μg and a total topotecan dose of 74.7±44.0 μg per eye. During the follow-up period, vitreous seeds in all affected eyes in both groups were controlled (100%), and no orbital or systemic metastases were observed. Compared with the double-drug group, the single-drug group exhibited fewer local adverse effects. The incidence of cataract was 0/15 and 9/19, while the incidence of phthisis bulbi was 0/15 and 6/19, respectively (both P<0.05). Some patients in both groups developed retinal pigment epithelial and choroidal atrophy, vascular occlusion or optic nerve atrophy, but the differences were not statistically significant (both P>0.05). The final globe-salvage rates were 14/15 in the single-drug group and 14/19 in the double-drug group. Conclusions: IVT can effectively treat vitreous seeds in RB. Compared with the regimen combining melphalan, the IVT monotherapy is associated with fewer intraocular adverse effects. 目的: 探讨玻璃体腔注射拓扑替康(IVT)与玻璃体腔注射美法仑(IVM)联合IVT治疗视网膜母细胞瘤(RB)玻璃体腔种植的有效性和安全性。 方法: 回顾性队列研究。收集2015年12月至2025年5月在复旦大学附属眼耳鼻喉科医院就诊并确诊的34例单眼玻璃体腔种植的RB患儿的临床资料。患儿均接受经静脉化学治疗或经动脉介入化学治疗后出现顽固性或复发性玻璃体腔种植。分析其基线资料、眼部特征及详细治疗经过。采用IVT(单药组)或IVT联合IVM(双药组)进行治疗,每4周1次,直至玻璃体腔种植消失或钙化稳定。主要结果指标为玻璃体腔种植控制情况及保眼率,同时观察玻璃体腔内化学治疗后眼部及全身不良反应。采用t检验、Mann-Whitney U检验和χ²检验或进行统计学分析,应用Kaplan-Meier法绘制保眼率曲线,采用Log-rank检验比较其差异。 结果: 共纳入34例患儿(34只眼),其中男性21例(61.8%)、女性13例(38.2%);初次诊断年龄为29.5(19.5,38.0)个月。双眼RB患儿8例(23.5%),均为单眼玻璃体腔种植且该眼接受玻璃体腔内化学治疗;单眼RB患儿26例(76.5%)。患眼中左眼15只(44.1%),右眼19只(55.9%);根据国际眼内RB分期为E期13只(38.2%),D期20只(58.8%),C期1只(3.0%)。单药组共15只眼(44.1%),初次诊断年龄21.0(11.0,30.0)个月,随访时间(19.0±10.0)个月,其中1只眼为C期,7只眼为D期,7只眼为E期,每只患眼注射(3.1±1.1)次,每只患眼注射拓扑替康总剂量为(89.3±34.3)μg。双药组共19只眼(55.9%),初次诊断年龄33.0(22.0,42.0)个月,随访时间(67.9±30.4)个月,其中13只眼为D期,6只眼为E期,每只患眼注射(5.0±1.7)次,每只患眼注射美法仑总剂量为(111.1±44.5)μg,拓扑替康总剂量为(74.7±44.0)μg。随访期两组所有患眼玻璃体腔种植均得到控制(100%),无眼眶或全身转移。单药组与双药组相比,局部不良反应更少。白内障的发生率分别为0/15和9/19,眼球萎缩的发生率分别为0/15和6/19(均P<0.05)。两组均有部分患儿出现视网膜脉络膜萎缩、血管闭塞、视神经萎缩,但差异均无统计学意义(均P>0.05)。单药组和双药组的最终保眼率分别为14/15和14/19,差异无统计学意义(P>0.05)。 结论: IVT能有效治疗RB玻璃体腔种植。与联合美法仑相比,单独采用拓扑替康的眼内不良反应更小。.
引用
- Lin XT, Chen HF, Liu Q, et al. [The efficacy of topotecan versus topotecan combined with melphalan in the treatment of vitreous seeds in retinoblastoma]. Zhonghua Yan Ke Za Zhi. 2025. PMID: 41218901. doi:10.3760/cma.j.cn112142-20250604-00264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。